CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes

Phase 2enicepatideNeutral
AI Analysis

Summary

Roche reported Phase 2 data for enicepatide, a mid-stage candidate acquired from Carmot Therapeutics, in overweight or obese patients with type 2 diabetes.

Clinical Trial Data

Phase

Phase 2

Importance:6/10
Sentiment:
0.00
Phase 2 datatype 2 diabetesGLP-1obesity
Related Companies

Read the original article

Published by Endpoints News on September 22, 2026 10:57 AM

Read Original